Venous Thromboembolism During Pregnancy* *Venous thromboembolism (VTE) during pregnancy has many parallels with disorders are considered to be at high risk for thrombosis VTE in nonpregnant individuals. The differences are emphasized. Various aspects of thrombosis in pregnancy have been well summarized in several secondary sources, including the version of this chapter in the third edition of this volume and in original papers in the clinical literature.9–13 I have consulted these secondary sources and journal articles while composing the present chapter, and I refer to both types of sources.

2004 ◽  
pp. 87-101
Author(s):  
Peter McPhedran
Keyword(s):  
Venous Thromboembolism ◽  
High Risk ◽  
Journal Articles ◽  
Secondary Sources ◽  
The Third ◽  
Clinical Literature ◽  
Risk For Thrombosis ◽  
In Pregnancy

scholarly journals Pneumonia in pregnancy

2021 ◽  
Vol 16 (S3) ◽  
pp. 36-39
Author(s):  
Delia Ioana CUDALBĂ ◽  
◽  
Brînduşa Ana CIMPOCA-RAPTIS ◽  
Anca Marina CIOBANU ◽  
Corina GICĂ ◽  
...  
Keyword(s):  
High Risk ◽  
Clinical Course ◽  
Review Article ◽  
Pulmonary Diseases ◽  
Common Disease ◽  
Journal Articles ◽  
Electronic Search ◽  
Changes In Pregnancy ◽  
Prompt Diagnosis ◽  
In Pregnancy

Pneumonia is a common disease worldwide and the coexistence with pregnancy increase its morbidity and mortality. Physiologic changes in pregnancy can augment susceptibility to pulmonary diseases and change their clinical course. This review article attempts to make an assessment of current information on the risks, maternal and fetal effects, etiology, clinical features and management of pneumonia in pregnancy. A systematic literature electronic search for journal articles and guidelines regarding pneumonia and respiratory disease in pregnancy was undertaken. Pathogens, clinical course and treatment of pneumonia in pregnancy is similar to the non-pregnant circumstances, with particular consideration on obstetric and fetal outcomes and drug safety during pregnancy. Prompt diagnosis and treatment reduce potential complications. Vaccination may reduce severity of pneumonia in high-risk pregnant patients.

scholarly journals Thromboembolic complications during pregnancy and delivery

2013 ◽  
Vol 66 (9-10) ◽  
pp. 417-423 ◽  
Author(s):  
Radmila Sparic ◽  
Biljana Lazovic ◽  
Zoran Stajic ◽  
Sanja Mazic ◽  
Marina Djelic ◽  
...  
Keyword(s):  
Risk Factors ◽  
Venous Thromboembolism ◽  
High Risk ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Central Place ◽  
Pulmonary Angiography ◽  
Pregnancy And Delivery ◽  
Pass Through ◽  
In Pregnancy

Introduction. Venous thromboembolism is one of the leading cause of maternal mortality worldwide. The incidence of venous thromboembolism is estimated at 0.76 to 1.72 per 100.000 pregnancies which is four times as great as the risk in nonpregnant women. The purpose of this article is to raise awareness of this frequent problem in pregnancy and provide a practical approach for the diagnosis, management, and prevention of venous thromboembolism during pregnancy and delivery. Risk factors. A number of risk factors for the development venous thromboembolism have been identified. The two most important risk factors for venous thromboembolism in pregnancy are thrombophilia and previous venous thromboembolism. Deep venous thrombosis in the majority of cases occurs in the lower extremities and pelvis. Diagnosis. As the clinical diagnosis of venous thromboembolism is unreliable, the women who are suspected of having deep venous thrombosis or pulmonary embolism should be examined promptly using imaging diagnostics. The first diagnostic method is Doppler ultrasound. Where available, individual authors recommend magnetic resonance venography, pulmonary angiography or computed tomography. Therapy. Unfractionated heparin or low-molecularweight heparin has a central place in the prevention and treatment of venous thromboembolism in pregnancy because they do not pass through the placenta, thus avoiding the risks likely to be induced by warfarin. The prevention of venous thromboembolism must focus on the patients known to be at high risk bearing in mind that the recommendations for prophylaxis, even in high-risk patients, are based on the limited data.

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM IN HIGH RISK SITUATIONS IN PREGNANCY

2005 ◽  
Vol 16 (1) ◽  
pp. 51-70 ◽  
Author(s):  
ANNE G McLEOD ◽  
CAMERON ELLIS
Keyword(s):  
Risk Factors ◽  
Venous Thromboembolism ◽  
High Risk ◽  
Pregnant Women ◽  
Signs And Symptoms ◽  
Multiple Gestation ◽  
Vein Thrombosis ◽  
Low Threshold ◽  
Deep Vein ◽  
In Pregnancy

Venous thromboembolism (VTE) is a leading cause of maternal mortality in the western developed world. VTE may present as deep vein thrombosis (DVT) or pulmonary embolism (PE) but if untreated can result in fatal PE. Although fatal PE is clearly the most significant consequence of VTE in pregnancy, DVT also often leads to morbidity related to the development of post-thrombotic syndrome (PTS). Pregnancy is an independent risk factor for VTE and the risk of VTE is 4–10 fold higher in pregnant women than in non-pregnant women of similar age. The puerperium represents a time of even higher risk. It is clear that many additional high-risk situations in pregnancy lower the threshold for thrombosis and warrant measures to prevent VTE and its complications. Risk factors for pregnancy-related VTE may be inherited or acquired. Acquired risk factors may be specifically related to the pregnancy or may have developed prior to pregnancy. Well-documented risk factors for pregnancy-related VTE include delivery by Caesarean section, previous VTE, and inherited or acquired thrombophilia. Other risk factors that have been identified include obesity, multiparity, multiple gestation, pre-eclampsia and medical conditions, such as sickle cell disease, that predispose to VTE. Our ability to diagnose VTE overall is poor as presenting signs and symptoms are extremely varied and unreliable. This is further complicated in pregnancy where signs and symptoms suggestive of VTE are common and invasive testing is more complicated. It is essential that physicians be vigilant in monitoring patients for the development of VTE and maintain a low threshold for considering thromboprophylaxis. Guidelines have recently been published by several medical societies to help with these difficult decisions. In this review the risk factors for the development of VTE in pregnancy will be discussed and guidelines for risk assessment presented. Management of patients who develop VTE in pregnancy is also outlined.

GESTOGENS IN CORPUS LUTEUM OF CATTLE

1960 ◽  
Vol XXXIII (III) ◽  
pp. 417-427 ◽  
Author(s):  
John Kristoffersen
Keyword(s):  
Corpus Luteum ◽  
Average Value ◽  
Spectrophotometric Methods ◽  
The Third ◽  
Quantitative Measurements ◽  
Before And After ◽  
Luteal Tissue ◽  
In Pregnancy

ABSTRACT By means of chromatographic and spectrophotometric methods progesterone and a substance closely similar to 20β-hydroxy-pregn-4-ene-3-one has been detected in luteal tissue from non-pregnant and pregnant cows. In 21 animals quantitative measurements based on a method giving an average net recovery of 56 per cent showed that in pregnancy the average progesterone content in the corpus luteum reached a maximum in the third to fifth month, with low values before and after this period. For 6 nonpregnant cows, the average value was 20.2 μg/g tissue, which is considerably higher than previous values reported in the literature. The relation between these findings and the bovine dependence on a functional corpus luteum in pregnancy is discussed, and it is pointed out that more information about the metabolism of progesterone in cattle is highly desirable.

scholarly journals Are children with SARS‐CoV‐2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients

2020 ◽  
Vol 67 (12) ◽  
Author(s):  
Maha Al‐Ghafry ◽  
Banu Aygun ◽  
Abena Appiah‐Kubi ◽  
Adrianna Vlachos ◽  
Gholamabbas Ostovar ◽  
...  
Keyword(s):  
High Risk ◽  
Pediatric Patients ◽  
Case Series ◽  
Risk For Thrombosis

scholarly journals May–Thurner Syndrome in Pregnancy-Associated Venous Thromboembolism

TH Open ◽  
2021 ◽  
Vol 05 (03) ◽  
pp. e251-e252
Author(s):  
Mateo Porres-Aguilar ◽  
Debabrata Mukherjee
Keyword(s):  
Venous Thromboembolism ◽  
In Pregnancy

scholarly journals Secondary sources of negative symptoms in those meeting criteria for a clinical high-risk syndrome

2021 ◽  
Author(s):  
Tina Gupta ◽  
Gregory P. Strauss ◽  
Henry R. Cowan ◽  
Andrea Pelletier-Baldelli ◽  
Lauren M. Ellman ◽  
...  
Keyword(s):  
High Risk ◽  
Negative Symptoms ◽  
Clinical High Risk ◽  
Secondary Sources

scholarly journals Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer

Healthcare ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 778
Author(s):  
Ann-Rong Yan ◽  
Indira Samarawickrema ◽  
Mark Naunton ◽  
Gregory M. Peterson ◽  
Desmond Yip ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Venous Thromboembolism ◽  
High Risk ◽  
Prediction Models ◽  
Poor Performance ◽  
Risk Models ◽  
Related Risk ◽  
Wide Range ◽  
Ambulatory Patients

Venous thromboembolism (VTE) is a significant cause of mortality in patients with lung cancer. Despite the availability of a wide range of anticoagulants to help prevent thrombosis, thromboprophylaxis in ambulatory patients is a challenge due to its associated risk of haemorrhage. As a result, anticoagulation is only recommended in patients with a relatively high risk of VTE. Efforts have been made to develop predictive models for VTE risk assessment in cancer patients, but the availability of a reliable predictive model for ambulate patients with lung cancer is unclear. We have analysed the latest information on this topic, with a focus on the lung cancer-related risk factors for VTE, and risk prediction models developed and validated in this group of patients. The existing risk models, such as the Khorana score, the PROTECHT score and the CONKO score, have shown poor performance in external validations, failing to identify many high-risk individuals. Some of the newly developed and updated models may be promising, but their further validation is needed.

Sign in / Sign up

Export Citation Format

Share Document